PAD
MCID: PRP027
MIFTS: 71

Peripheral Vascular Disease (PAD)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Peripheral Vascular Disease

MalaCards integrated aliases for Peripheral Vascular Disease:

Name: Peripheral Vascular Disease 40 12 15 37 17
Peripheral Arterial Disease 40 42 3 62 17
Arterial Occlusive Disease 40 12 15 17
Arterial Occlusive Diseases 54 44 71
Peripheral Vascular Diseases 54 71
Pad 40 3
Peripheral Occlusive Disease 40
Peripheral Arterial Diseases 71
Occlusive Arterial Disease 6
Helicobacter Infections 71

Classifications:



External Ids:

Disease Ontology 12 DOID:341
ICD9CM 34 443.81
MeSH 44 D001157
SNOMED-CT 67 195624006 2929001
ICD10 32 I73.8 I73.9
UMLS 71 C0003838 C0031115 C0079487 more

Summaries for Peripheral Vascular Disease

MedlinePlus : 42 Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. The cause of PAD is atherosclerosis. This happens when plaque builds up on the walls of the arteries that supply blood to the arms and legs. Plaque is a substance made up of fat and cholesterol. It causes the arteries to narrow or become blocked. This can reduce or stop blood flow, usually to the legs. If severe enough, blocked blood flow can cause tissue death and can sometimes lead to amputation of the foot or leg. The main risk factor for PAD is smoking. Other risk factors include older age and diseases like diabetes, high blood cholesterol, high blood pressure, heart disease, and stroke. Many people who have PAD don't have any symptoms. If you have symptoms, they may include Pain, numbness, achiness, or heaviness in the leg muscles. This happens when walking or climbing stairs. Weak or absent pulses in the legs or feet Sores or wounds on the toes, feet, or legs that heal slowly, poorly, or not at all A pale or bluish color to the skin A lower temperature in one leg than the other leg Poor nail growth on the toes and decreased hair growth on the legs Erectile dysfunction, especially among men who have diabetes PAD can increase your risk of heart attack, stroke, and transient ischemic attack. Doctors diagnose PAD with a physical exam and heart and imaging tests. Treatments include lifestyle changes, medicines, and sometimes surgery. Lifestyle changes include dietary changes, exercise, and efforts to lower high cholesterol levels and high blood pressure. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Peripheral Vascular Disease, also known as peripheral arterial disease, is related to buerger disease and diabetic angiopathy, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Peripheral Vascular Disease is APOB (Apolipoprotein B), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Lipoprotein metabolism. The drugs Acetylcysteine and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include Bone, heart and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A vascular disease that is characterized by obstruction of larger arteries not within the coronary, aortic arch vasculature, or brain.

CDC : 3 Peripheral Arterial Disease (PAD) in the Legs or lower extremities is the narrowing or blockage of the vessels that carry blood from the heart to the legs. It is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can occur in any blood vessel, but it is more common in the legs than the arms.

PubMed Health : 62 About peripheral arterial disease: Peripheral arterial disease (P.A.D.) is a disease in which plaque (plak) builds up in the arteries that carry blood to your head, organs, and limbs. Plaque is made up of fat, cholesterol, calcium, fibrous tissue, and other substances in the blood. When plaque builds up in the body's arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). Over time, plaque can harden and narrow the arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. P.A.D. usually affects the arteries in the legs, but it also can affect the arteries that carry blood from your heart to your head, arms, kidneys, and stomach. This article focuses on P.A.D. that affects blood flow to the legs.

Related Diseases for Peripheral Vascular Disease

Diseases related to Peripheral Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 863)
# Related Disease Score Top Affiliating Genes
1 buerger disease 32.8 VEGFA VCAM1 CRP
2 diabetic angiopathy 32.3 VWF THBD SELE
3 intermittent claudication 31.4 VWF VEGFA SERPINC1 SELP PF4 IL6
4 limb ischemia 31.4 VWF VEGFA SELE PLAT IL6 F2
5 ischemia 31.3 VEGFA SELP SELE PLAT ACE
6 vascular disease 31.3 VWF VEGFA VCAM1 THBD SERPINC1 SELP
7 carotid stenosis 31.2 VWF VEGFA VCAM1 SELP SELE CRP
8 arteriosclerosis obliterans 31.1 VCAM1 SELP IL6
9 proteinuria, chronic benign 31.1 VEGFA ALB ACE
10 hypertriglyceridemia, familial 31.0 CETP APOB APOA1
11 end stage renal disease 31.0 VEGFA THBD IL6 CRP APOB ALB
12 aortic aneurysm, familial abdominal, 1 31.0 VCAM1 SERPINC1 IL6 CRP CETP ALB
13 peripheral nervous system disease 31.0 VEGFA IL6 CRP ALB ACE
14 congestive heart failure 31.0 VEGFA IL6 CRP ALB ACE
15 arteries, anomalies of 31.0 VEGFA VCAM1 IL6 F3 CRP APOB
16 peripheral artery disease 31.0 VWF VEGFA VCAM1 SELP IL6 F3
17 collagen disease 30.9 VWF THBD CRP
18 coronary heart disease 1 30.9 LPA CRP CETP APOB APOA1 ACE
19 angina pectoris 30.9 PLAT IL6 F3 CRP APOA1 ACE
20 hypercholesterolemia, familial, 1 30.9 LPA CRP CETP APOB APOA1 ACE
21 generalized atherosclerosis 30.9 VWF IL6 CRP APOB ALB ACE
22 carotid artery disease 30.9 THBD SELE LPA F3 CRP APOB
23 chronic ulcer of skin 30.8 VEGFA IL6 CRP ALB
24 cerebral atherosclerosis 30.8 CRP APOB APOA1 ACE
25 polyarteritis nodosa 30.8 VCAM1 SELP SELE IL6 CRP
26 cardiogenic shock 30.8 PLAT IL6
27 rheumatic heart disease 30.8 VCAM1 IL6 ACE
28 microvascular complications of diabetes 5 30.7 VEGFA VCAM1 ALB ACE
29 glucose intolerance 30.7 IL6 CRP ALB ACE
30 hyperglycemia 30.7 VCAM1 SELE IL6 APOB ALB
31 branch retinal artery occlusion 30.7 VEGFA SERPINC1 F2 CRP
32 vasculitis 30.7 VWF VCAM1 THBD SELP SELE IL6
33 antithrombin iii deficiency 30.7 SERPINC1 PF4 F2
34 type 1 diabetes mellitus 30.7 VEGFA IL6 CRP CETP APOB APOA1
35 hyperuricemia 30.7 CRP APOB ALB
36 venous insufficiency 30.7 VWF VEGFA VCAM1 SELP PLAT F2
37 intracranial thrombosis 30.7 VWF SERPINC1 SELP PLAT F3 F2
38 chronic venous insufficiency 30.7 VEGFA VCAM1 SELP PLAT F2 CRP
39 thrombophilia due to activated protein c resistance 30.7 VWF THBD SERPINC1 F3 F2
40 sickle cell disease 30.7 VWF VCAM1 SELP SELE PPBP
41 takayasu arteritis 30.6 VCAM1 THBD SELE IL6 CRP
42 arteriosclerosis 30.6 VCAM1 THBD SERPINC1 SELP SELE LPA
43 aortic atherosclerosis 30.6 LPA CETP ACE
44 moyamoya disease 1 30.6 VWF VEGFA SERPINC1 PLAT F3 F2
45 homocysteinemia 30.6 VWF VCAM1 THBD SERPINC1 F2 CRP
46 lipid metabolism disorder 30.6 SELE LPA IL6 CRP CETP APOB
47 cholesterol embolism 30.6 SERPINC1 F2 CRP ACE
48 deficiency anemia 30.6 SERPINC1 SELP IL6 CRP ALB ACE
49 compartment syndrome 30.6 SERPINC1 IL6 F3 F2 CRP ALB
50 sudden sensorineural hearing loss 30.6 IL6 F2

Comorbidity relations with Peripheral Vascular Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 94)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Vascular Insufficiency of Intestine Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Autonomic Nervous System Disease
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Renovascular Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Buerger Disease Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebrovascular Disease Chronic Intestinal Vascular Insufficiency
Chronic Pulmonary Heart Disease Chronic Ulcer of Skin
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Polyneuropathy
Dressler's Syndrome Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gas Gangrene
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hyperlipoproteinemia, Type V Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis

Graphical network of the top 20 diseases related to Peripheral Vascular Disease:



Diseases related to Peripheral Vascular Disease

Symptoms & Phenotypes for Peripheral Vascular Disease

UMLS symptoms related to Peripheral Vascular Disease:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Peripheral Vascular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 ACE ALB APOA1 APOB CRP F2
2 homeostasis/metabolism MP:0005376 10.33 ACE ALB APOA1 APOB CRP F2
3 cellular MP:0005384 10.3 ALB APOA1 APOB F2 F3 IL6
4 immune system MP:0005387 10.24 ACE ALB APOB CRP F2 F3
5 hematopoietic system MP:0005397 10.21 ACE F3 IL6 PF4 PLAT SELE
6 mortality/aging MP:0010768 10 ACE ALB APOB F2 F3 IL6
7 integument MP:0010771 9.97 APOA1 F2 F3 IL6 PLAT SELE
8 liver/biliary system MP:0005370 9.96 ACE ALB APOA1 APOB IL6 SELE
9 muscle MP:0005369 9.56 ALB APOB F2 F3 IL6 PLAT
10 respiratory system MP:0005388 9.23 F2 F3 IL6 PLAT SELE SELP

Drugs & Therapeutics for Peripheral Vascular Disease

PubMed Health treatment related to Peripheral Vascular Disease: 62

Treatments for peripheral arterial disease (P.A.D.) include lifestyle changes, medicines, and surgery or procedures. The overall goals of treating P.A.D. include reducing symptoms, improving quality of life, and preventing complications. Treatment is based on your signs and symptoms, risk factors, and results from a physical exam and tests. Treatment may slow or stop disease progress and reduce the risk of complications. Without treatment, P.A.D. can cause sores or gangrene (tissue death). In extreme cases, it may be necessary to remove part of the leg or foot (amputation ).

Drugs for Peripheral Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Losartan Approved Phase 4 114798-26-4 3961
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Ramipril Approved Phase 4 87333-19-5 5362129
14
Ezetimibe Approved Phase 4 163222-33-1 150311
15
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
16
Thrombin Approved, Investigational Phase 4
17
Allopurinol Approved Phase 4 315-30-0 2094
18
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
19
Defibrotide Approved, Investigational Phase 4 83712-60-1
20
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
21
Testosterone enanthate Approved Phase 4 315-37-7 9416
22
Testosterone Approved, Investigational Phase 4 58-22-0 6013
23
Methyltestosterone Approved Phase 4 58-18-4 6010
24
Morphine Approved, Investigational Phase 4 57-27-2 5288826
25
Clonidine Approved Phase 4 4205-90-7 2803
26
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
27
Tranexamic Acid Approved Phase 4 1197-18-8 5526
28
Pantoprazole Approved Phase 4 102625-70-7 4679
29
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
30
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
31
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
32
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
33
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
34
Loperamide Approved Phase 4 53179-11-6 3955
35
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
36
Coal tar Approved Phase 4 8007-45-2
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
40
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
41
Evolocumab Approved Phase 4 1256937-27-5
42
Dalteparin Approved Phase 4 9005-49-6
43
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
44
Iron Approved Phase 4 7439-89-6 23925 29936
45
Glucagon Approved Phase 4 16941-32-5
46
Metronidazole Approved Phase 4 443-48-1 4173
47
Liraglutide Approved Phase 4 204656-20-2 44147092
48
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
49
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
50
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479

Interventional clinical trials:

(show top 50) (show all 1440)
# Name Status NCT ID Phase Drugs
1 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
2 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
3 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
4 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
5 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
6 In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions Unknown status NCT02678065 Phase 4
7 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
8 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
9 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
10 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
11 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Unknown status NCT02842424 Phase 4 Ramipril
12 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
13 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
14 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
15 Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs Unknown status NCT01424020 Phase 4
16 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
17 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
18 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
19 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
20 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
21 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
22 Effect of Topical Anesthesia on Patient's Pain Discomfort and Radial Artery Spasm in Transradial Catheterization Unknown status NCT03501212 Phase 4 Topical Anesthetic;Placebo
23 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
24 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
25 Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial Unknown status NCT03208426 Phase 4 Esomeprazole (S14);Esomeprazole (BQ10);Amoxicillin (ST14);Clarithromycin (ST14);Metronidazole (ST14);dibismuth trioxide 120mg (BQ10);Metronidazole (BQ10);tetracycline (BQ10)
26 Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy Unknown status NCT02894268 Phase 4 Doxycycline;Furazolidone;Esomeprazole;Colloidal Bismuth Subcitrate;Sensitivity antibiotics
27 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
28 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
29 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
30 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
31 Analysis of the Impact of Helicobacter Pylori Infection and Eradication on Salivary Microbiome in Adults by 16S Pyrosequencing Unknown status NCT03730766 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
32 Efficacy and Safety of a 14-day Modified Sequential Therapy for Refractory Helicobacter Pylori Infection: an Open Randomized Pilot Study Unknown status NCT03658733 Phase 4 esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days);rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
33 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4
34 Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial Completed NCT00715416 Phase 4
35 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD Completed NCT01952756 Phase 4 Cilostazol;Dummy Placebo
36 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
37 Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study Completed NCT01556542 Phase 4
38 Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study Completed NCT02548650 Phase 4 Vorapaxar;Clopidogrel;Aspirin
39 GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease Completed NCT00228384 Phase 4
40 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4
41 Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease Completed NCT01041729 Phase 4 Atorvastatin;Standard Medical Treatment
42 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
43 A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA) Completed NCT01075217 Phase 4 iopamidol;iodixanol
44 Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries Completed NCT00180505 Phase 4
45 Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis Completed NCT00837954 Phase 4
46 4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
47 Femoral Artery In-Stent Restenosis (FAIR) Trial Completed NCT01305070 Phase 4
48 The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis Completed NCT01108861 Phase 4
49 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
50 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4

Search NIH Clinical Center for Peripheral Vascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


alteplase
BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
cilostazol
Cimetidine
Cimetidine Hydrochloride
Cyclandelate
Epoprostenol
Epoprostenol Sodium
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
lansoprazole
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Niacin
Niacinamide
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
Papaverine
Papaverine Hydrochloride
rabeprazole
Streptokinase
Tolazoline
Tolazoline Hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral Vascular Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Peripheral Vascular Disease:
ACY001, bone marrow-derived hematopoietic stem cells for coronary artery occlusions
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Endothelial progenitor cells for peripheral artery disease
Enriched bone marrow-derived progenitor cells for ischemic diseases
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
MultiStem, bone marrow-derived cells for peripheral vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
TGI PVG, adipose-derived stem cell-coated vascular graft for peripheral vascular disease
VASCUGEL, aortic endothelial cells for vascular injury and disease
Embryonic/Adult Cultured Cells Related to Peripheral Vascular Disease:
Bone marrow-derived CD133+ stem cells
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone marrow-derived mononuclear cells (family)
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Peripheral blood-derived endothelial progenitor cells PMIDs: 10725398
Bone marrow-derived progenitor cells
Genetically modified vein-derived endothelial cells
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived smooth muscle
MultiGeneAngio, transduced vein-derived endothelial cells
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285 23307829
Peripheral blood-derived hematopoietic stem cells
Adipose-derived stromal cells PMIDs: 8207032 23350681
Aortic endothelial cells cultured in matrix PMIDs: 7667257
Aortic endothelial cells cultured in matrix (VASCUGEL) PMIDs: 7667257

Cochrane evidence based reviews: arterial occlusive diseases

Genetic Tests for Peripheral Vascular Disease

Anatomical Context for Peripheral Vascular Disease

MalaCards organs/tissues related to Peripheral Vascular Disease:

40
Heart, Endothelial, Kidney, Bone Marrow, Bone, Skin, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Peripheral Vascular Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Peripheral Vascular Disease

Articles related to Peripheral Vascular Disease:

(show top 50) (show all 17613)
# Title Authors PMID Year
1
Drug-Coated Devices for Peripheral Arterial Disease. 42 61
33502835 2021
2
Feasibility and safety of automated CO2 angiography in peripheral arterial interventions. 42
33466210 2021
3
COMORBID CONDITION - DIABETES MELLITUS WITH CO-EXISTENT RAYNAUD'S SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS. 42
33526731 2020
4
Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. 54 61
20116913 2010
5
Predicting six-month mortality for patients who are on maintenance hemodialysis. 54 61
19965531 2010
6
Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. 61 54
19478100 2009
7
Role of von Willebrand factor in vascular disease. 54 61
19151843 2009
8
Exercise and limitations in physical activity levels among new dialysis patients in the United States: an epidemiologic study. 54 61
19041586 2008
9
Effects of peripheral vascular intervention on ischemia-modified albumin. 61 54
17627187 2007
10
ACE gene polymorphism in peripheral vascular disease. 54 61
17611909 2007
11
Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. 61 54
17556876 2007
12
Evaluation of a protocol for prevention of facility-acquired heel pressure ulcers. 54 61
17413835 2007
13
A perspective on telmisartan and cardiovascular risk. 54 61
17938615 2007
14
Peripheral arterial disease: a review of disease awareness and management. 54 61
17296541 2006
15
Optimal medical management of peripheral arterial disease. 54 61
16959725 2006
16
The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. 61 54
16046516 2005
17
The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. 54 61
15855200 2005
18
A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. 61 54
16103720 2005
19
Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. 54 61
15569327 2004
20
Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. 61 54
15265817 2004
21
[The metabolic syndrome in patients with type 1 diabetes mellitus. Associations with cardiovascular risk factors and cardiovascular morbidity]. 54 61
15340731 2004
22
Elevated soluble cell adhesion molecules E-selectin and intercellular cell adhesion molecule-1 in type-2 diabetic patients with and without asymptomatic peripheral arterial disease. 61 54
15507889 2004
23
[Diabetes and atherosclerotic coronary damage in uremia]. 54 61
15356846 2004
24
Relationship between diabetes mellitus and degree of coronary artery disease in uraemic patients investigated with coronary angiography. 54 61
12703884 2003
25
Hypertension as a determinant of survival for patients treated with home dialysis. 54 61
12427157 2002
26
Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. 61 54
12419932 2002
27
Association of serum albumin and atherosclerosis in chronic hemodialysis patients. 54 61
12324906 2002
28
Minimally invasive vein harvesting significantly reduces pain and wound morbidity. 61 54
12204728 2002
29
Pre-dialysis clinic attendance improves quality of life among hemodialysis patients. 54 61
11934351 2002
30
Smoking causes a dose-dependent increase in granulocyte-bound L-selectin. 54 61
12165281 2002
31
The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. 54 61
11941273 2002
32
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. 61 54
11835907 2002
33
Determinants of physical performance in ambulatory patients on hemodialysis. 54 61
11576377 2001
34
Cross-sectional and longitudinal predictors of serum albumin in hemodialysis patients. 54 61
11044233 2000
35
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. 54 61
10933355 2000
36
Prostaglandin E1-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular disease. 54 61
11037715 2000
37
The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. 61 54
10894450 2000
38
Elevated levels of soluble E-selectin in diabetic patients with severe symptomatic peripheral arterial occlusive disease requiring angioplasty. A possible role in diabetic vascular disease? 61 54
10905802 2000
39
The effect of small solute clearances on survival of anuric peritoneal dialysis patients. 54 61
10809241 2000
40
Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. 61 54
10582542 1999
41
A randomized trial of endoscopic versus open saphenous vein harvest in coronary bypass surgery. 61 54
10543556 1999
42
Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. 61 54
9719061 1998
43
Total body nitrogen predicts long-term mortality in haemodialysis patients--a single-centre experience. 54 61
9681720 1998
44
[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension]. 61 54
9813738 1998
45
Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. 61 54
9241735 1997
46
von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? 61 54
9205537 1997
47
Cell adhesion molecules and insulin-like growth factor-1 in vascular disease. 61 54
9152314 1997
48
Urinary albumin excretion rate and cardiovascular disease in Spaniard type 2 diabetic patients. 54 61
9229197 1997
49
Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. 61 54
9112880 1997
50
Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. 54 61
9051381 1997

Variations for Peripheral Vascular Disease

Expression for Peripheral Vascular Disease

Search GEO for disease gene expression data for Peripheral Vascular Disease.

Pathways for Peripheral Vascular Disease

Pathways related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 VWF VEGFA THBD SERPINC1 SELP SELE
2
Show member pathways
12.47 LPA CETP APOB APOA1 ALB
3
Show member pathways
12.19 PPBP PF4 IL6 APOB
4
Show member pathways
12.13 THBD SELP SELE PF4 F2 APOB
5
Show member pathways
12.13 PLAT IL6 F2 CRP APOB APOA1
6 12.01 VWF THBD SERPINC1 PLAT F3 F2
7 12 VEGFA VCAM1 THBD SELE PLAT
8 11.95 VEGFA VCAM1 IL6 ALB
9
Show member pathways
11.88 LPA CETP APOB APOA1
10
Show member pathways
11.7 VWF THBD SERPINC1 PLAT PF4 F3
11 11.63 VEGFA VCAM1 THBD SELE IL6 F3
12
Show member pathways
11.6 VEGFA VCAM1 SELE IL6
13 11.48 VCAM1 SELP SELE IL6
14 11.4 SELP PLAT LPA IL6 APOB
15 11.37 F2 APOA1 ALB
16 11.3 VCAM1 SELE IL6 APOA1

GO Terms for Peripheral Vascular Disease

Cellular components related to Peripheral Vascular Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.1 VWF VCAM1 SERPINC1 PLAT F2 CETP
2 cell surface GO:0009986 9.93 VEGFA VCAM1 THBD PLAT F3 APOA1
3 external side of plasma membrane GO:0009897 9.89 VCAM1 THBD SELP F2 ACE
4 extracellular region GO:0005576 9.86 VWF VEGFA SERPINC1 PPBP PLAT PF4
5 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 IL6 F2 APOB APOA1 ALB
6 collagen-containing extracellular matrix GO:0062023 9.8 VWF SERPINC1 PLAT PF4 F3 F2
7 blood microparticle GO:0072562 9.73 SERPINC1 F2 APOA1 ALB
8 extracellular space GO:0005615 9.6 VWF VEGFA VCAM1 THBD SERPINC1 SELP
9 platelet alpha granule lumen GO:0031093 9.55 VWF VEGFA PPBP PF4 ALB
10 high-density lipoprotein particle GO:0034364 9.54 CETP APOB